Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma

被引:0
作者
Luca, Stefano [1 ,2 ]
Pignata, Giovanna [3 ]
Cioce, Alessandro [1 ,2 ]
Salzillo, Cecilia [2 ,4 ]
De Cecio, Rossella [3 ]
Ferrara, Gerardo [3 ]
Della Corte, Carminia Maria [5 ]
Morgillo, Floriana [5 ]
Fiorelli, Alfonso [6 ]
Montella, Marco [1 ]
Franco, Renato [1 ]
机构
[1] Univ Campania Luigi Vanvitelli, Dept Mental & Phys Hlth & Prevent Med, Pathol Unit, I-80138 Naples, Italy
[2] Univ Campania Luigi Vanvitelli, Dept Expt Med, PhD Course Publ Hlth, I-80138 Naples, Italy
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, I-80131 Naples, Italy
[4] Univ Bari Aldo Moro, Dept Precis & Regenerat Med & Ionian Area, Pathol Unit, I-70121 Bari, Italy
[5] Univ Campania Luigi Vanvitelli, Dept Precis Med, Med Oncol, I-80138 Naples, Italy
[6] Univ Campania Luigi Vanvitelli, Dept Translat Med, Thorac Surg Unit, I-80138 Naples, Italy
关键词
pleural mesothelioma; malignant; histopathology; molecular tests; IN-SITU HYBRIDIZATION; MALIGNANT MESOTHELIOMA; BAP1; IMMUNOHISTOCHEMISTRY; DIFFERENTIAL-DIAGNOSIS; HOMOZYGOUS DELETION; SARCOMATOID MESOTHELIOMA; EPITHELIOID MESOTHELIOMA; LYMPHOHISTIOCYTOID MESOTHELIOMA; P16; FISH; BRCA1-ASSOCIATED PROTEIN-1;
D O I
10.3390/cancers17030481
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant pleural mesothelioma (MPM) still represents a complex diagnostic challenge for pathologists in routine practice. This diagnosis requires a multidisciplinary approach, and pathological evaluation is mandatory. The histopathological diagnosis is stepwise and should be based on morphological and immunohistochemical assessment, sometimes associated with molecular tests, and supported by clinical and radiological findings. A correct morphological approach aims to exclude pleural metastasis or benign mesothelial proliferations, which are the main differential diagnoses. While certain histological features are diagnostic of MPM, others are highly suggestive but not definitive. Immunohistochemistry plays a pivotal role, with a panel of both traditional and newer markers being used to assess mesothelial differentiation and to differentiate malignant from benign proliferations. In more challenging cases, molecular tests, such as fluorescent in situ hybridization (FISH) to detect CDKN2A deletion, can be helpful in distinguishing malignant from benign pleural lesions. This review summarizes the key morphological, immunohistochemical, and molecular features that should be considered when pleural biopsy samples are examined, with the aim of improving diagnostic accuracy in this complex area.
引用
收藏
页数:25
相关论文
共 164 条
  • [1] Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
    Abutaily, AS
    Addis, BJ
    Roche, WR
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (09) : 662 - 668
  • [2] Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma
    Alchami, Fouad Sami
    Attanoos, Richard Luther
    Bamber, Andrew Richard
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2017, 70 (02) : 179 - 182
  • [3] The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review
    Ali, Greta
    Bruno, Rossella
    Fontanini, Gabriella
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S276 - S284
  • [4] The Diagnosis of Pleural Tumors Other Than Mesothelioma
    Attanoos, Richard Luther
    Pugh, Matthew Richard
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (08) : 902 - 913
  • [5] Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms
    Attanoos, RL
    Dojcinov, SD
    Webb, R
    Gibbs, AR
    [J]. HISTOPATHOLOGY, 2000, 37 (03) : 224 - 231
  • [6] Pleural mesothelioma classification update
    Beasley, Mary Beth
    Galateau-Salle, Francoise
    Dacic, Sanja
    [J]. VIRCHOWS ARCHIV, 2021, 478 (01) : 59 - 72
  • [7] Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas
    Berg, Kyra B.
    Dacic, Sanja
    Miller, Caitlyn
    Cheung, Simon
    Churg, Andrew
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (12) : 1549 - 1553
  • [8] GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung
    Berg, Kyra B.
    Churg, Andrew
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (09) : 1221 - 1225
  • [9] The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
    Bott, Matthew
    Brevet, Marie
    Taylor, Barry S.
    Shimizu, Shigeki
    Ito, Tatsuo
    Wang, Lu
    Creaney, Jenette
    Lake, Richard A.
    Zakowski, Maureen F.
    Reva, Boris
    Sander, Chris
    Delsite, Robert
    Powell, Simon
    Zhou, Qin
    Shen, Ronglai
    Olshen, Adam
    Rusch, Valerie
    Ladanyi, Marc
    [J]. NATURE GENETICS, 2011, 43 (07) : 668 - U81
  • [10] A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas
    Brcic, Luka
    Le Stang, Nolwenn
    Gallob, Florian
    Pissaloux, Daniel
    Sequeiros, Ruth
    Paindavoine, Sandrine
    Pairon, Jean Claude
    Karanian, Marie
    Dacic, Sanja
    Girard, Nicolas
    Churg, Andrew
    Tirode, Franck
    Galateau-Salle, Francoise
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (03) : 313 - 322